아시아태평양의 희귀질환 유전자 검사 시장 : 분석 및 예측(2023-2033년)

The Asia Pacific Rare Disease Genetic Testing Market Expected to Reach $2.40 Billion by 2033

Introduction to Asia-Pacific Rare Disease Genetic Testing Market

The Asia-Pacific rare disease genetic testing market was valued at $0.58 billion in 2023 and is anticipated to reach $2.40 billion by 2033, witnessing a CAGR of 15.25% during the forecast period 2023-2033. Advanced technologies like whole-genome sequencing (WGS) and whole-exome sequencing (WES) analyze an individual's entire genetic code (genome) or specific protein-coding regions (exome), respectively. They aid in detecting genetic variations, mutations, or abnormalities linked to rare diseases.

Market Introduction

The Asia-Pacific (APAC) rare disease genetic testing market is witnessing notable growth driven by various factors. Increased awareness, advancements in genetic testing technologies, and rising healthcare expenditure contribute to market expansion. Moreover, the region's large population base and diverse genetic profiles present significant opportunities for genetic testing providers. Government initiatives aimed at improving healthcare infrastructure and expanding access to genetic testing services further propel market growth. Additionally, collaborations between healthcare organizations, research institutions, and industry players facilitate the development and adoption of innovative genetic testing solutions tailored to the region's specific needs. With a growing focus on precision medicine and personalized healthcare, the APAC rare disease genetic testing market is poised for continued expansion and innovation in the foreseeable future.

Market Segmentation:

Segmentation 1: by Disease Type

• Gastroenterology Disease
• Endocrine and Metabolism Disease
• Cardiovascular Disease
• Neurology Disease
• Hematology and Oncology Disease
• Dermatology Disease
• Other Diseases

Segmentation 2: by Technology

• Sanger Sequencing
• PCR
• NGS
• Microarrays
• Others (Targeted Cytogenetics, Karyotyping, and FISH)

Segmentation 3: by Country

• Japan
• India
• China
• South Korea
• Australia
• Singapore
• Rest-of-Asia-Pacific

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The APAC rare disease genetic testing market has been extensively segmented based on various categories, such as disease type, technology, and country. This can help readers understand which segments account for the largest share and which are well-positioned to grow in the coming years.

Competitive Strategy: The APAC rare disease genetic testing market has numerous established players paving their way into providing tests, panels, and assays in the market. Key players in the global rare disease genetic testing market analyzed and profiled in the study involve established players offering various disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Some of the prominent names established in this market are:

• 3billion, Inc.
• Konica Minolta (Ambry Genetics, Inc.)
• BGI Group
• Strand Life Science Pvt Ltd.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1 Market

• 1.1 Market Outlook
  • 1.1.1 Product Definition
  • 1.1.2 Inclusion and Exclusion Criteria
    • 1.1.2.1 Inclusion Criteria
    • 1.1.2.2 Exclusion Criteria
  • 1.1.3 Market Overview
    • 1.1.3.1 Market Footprint
    • 1.1.3.2 Market Size and Future Growth Potential
  • 1.1.4 COVID-19 Impact on the Market
    • 1.1.4.1 Impact on Research and Clinical Operations
    • 1.1.4.2 COVID-19 Impact: Current Scenario of the Market
• 1.2 Industry Analysis
  • 1.2.1 Regulatory Framework
    • 1.2.1.1 Legal Requirements and Framework in Asia-Pacific
      • 1.2.1.1.1 Japan
      • 1.2.1.1.2 China
      • 1.2.1.1.3 India
      • 1.2.1.1.4 Taiwan
  • 1.2.2 Patent Analysis
    • 1.2.2.1 Patent Filing Trend (by Country)
    • 1.2.2.2 Patent Filing Trend (by Year)
  • 1.2.3 Funding Scenario
• 1.3 Market Dynamics
  • 1.3.1 Overview
  • 1.3.2 Market Drivers
    • 1.3.2.1 Rapid Technological Advancements in Rare Disease Diagnosis
    • 1.3.2.2 Rising Prevalence of Genetic Disorders and Congenital Disorders
    • 1.3.2.3 Growing Recognition and Emphasis on Early Detection and Prevention of Rare Diseases in Pediatric Populations
  • 1.3.3 Market Challenges
    • 1.3.3.1 Lack of Consolidation of Information Leading to Difficulty in Diagnosis
    • 1.3.3.2 Significant Capital Requirement for Research and Development Hindering Global Expansion Efforts
  • 1.3.4 Market Opportunities
    • 1.3.4.1 Whole Genome Sequencing Putting an End to the Rare Disease Genetic Testing Odysseys
    • 1.3.4.2 AI-Based Diagnostic Tools Diagnosing Rare Diseases by Identifying Potential Diagnoses
    • 1.3.4.3 Transitioning toward Increased Genetics Coverage in Reimbursement Policies

2 Rare Disease Genetic Testing Market (by Region)

• 2.1 Asia-Pacific Rare Disease Genetic Testing Market
  • 2.1.1 Market Dynamics
    • 2.1.1.1 Impact Analysis
  • 2.1.2 Market Size and Forecast
    • 2.1.2.1 Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type)
    • 2.1.2.2 Asia-Pacific Rare Disease Genetic Testing Market (by Technology)
    • 2.1.2.3 Asia-Pacific Rare Disease Genetic Testing Market (by Country)
      • 2.1.2.3.1 Japan
        • 2.1.2.3.1.1 Market Dynamics
        • 2.1.2.3.1.2 Market Size and Forecast
        • 2.1.2.3.1.2.1 Japan Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.1.2.2 Japan Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.2 China
        • 2.1.2.3.2.1 Market Dynamics
        • 2.1.2.3.2.2 Market Size and Forecast
        • 2.1.2.3.2.2.1 China Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.2.2.2 China Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.3 Australia
        • 2.1.2.3.3.1 Market Dynamics
        • 2.1.2.3.3.2 Market Size and Forecast
        • 2.1.2.3.3.2.1 Australia Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.3.2.2 Australia Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.4 South Korea
        • 2.1.2.3.4.1 Market Dynamics
        • 2.1.2.3.4.2 Market Size and Forecast
        • 2.1.2.3.4.2.1 South Korea Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.4.2.2 South Korea Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.5 India
        • 2.1.2.3.5.1 Market Dynamics
        • 2.1.2.3.5.2 Market Size and Forecast
        • 2.1.2.3.5.2.1 India Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.5.2.2 India Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.6 Singapore
        • 2.1.2.3.6.1 Market Dynamics
        • 2.1.2.3.6.2 Market Size and Forecast
        • 2.1.2.3.6.2.1 Singapore Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.6.2.2 Singapore Rare Disease Genetic Testing Market (by Technology)
      • 2.1.2.3.7 Rest-of-Asia-Pacific
        • 2.1.2.3.7.1 Market Dynamics
        • 2.1.2.3.7.2 Market Size and Forecast
        • 2.1.2.3.7.2.1 Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Disease Type)
        • 2.1.2.3.7.2.2 Rest-of-Asia-Pacific Rare Disease Genetic Testing Market (by Technology)

3 Company Profiles

• 3.1 Overview
  • 3.1.1 3billion, Inc.
    • 3.1.1.1 Company Overview
    • 3.1.1.2 Role of 3billion, Inc. in the Rare Disease Genetic Testing Market
    • 3.1.1.3 Recent Developments
    • 3.1.1.4 Analyst Perspective
  • 3.1.2 Konica Minolta (Ambry Genetics, Inc.)
    • 3.1.2.1 Company Overview
    • 3.1.2.2 Role of Konica Minolta (Ambry Genetics, Inc.) in the Rare Disease Genetic Testing Market
    • 3.1.2.3 Financials
    • 3.1.2.4 Recent Developments
    • 3.1.2.5 Analyst Perspective
  • 3.1.3 BGI Group
    • 3.1.3.1 Company Overview
    • 3.1.3.2 Role of BGI Group in the Rare Disease Genetic Testing Market
    • 3.1.3.3 Financials
    • 3.1.3.4 Recent Developments
    • 3.1.3.5 Analyst Perspective
  • 3.1.4 Strand Life Science Pvt Ltd.
    • 3.1.4.1 Company Overview
    • 3.1.4.2 Role of Strand Life Science Pvt Ltd. in the Rare Disease Genetic Testing Market
    • 3.1.4.3 Recent Developments
    • 3.1.4.4 Analyst Perspective